COMMUNIQUÉS West-GlobeNewswire

XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
18/03/2026
Portfolio receipts : • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties up 68% versus full [...]
Communiqué de presse : Le venglustat de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3
18/03/2026
Le venglusta t de Sanofi a reçu la désignation de thérapie innovante aux États-Unis pour la maladie de Gaucher de type 3 Paris, le 18 mars 2026 . La Food and Drug Administration (FDA) des États-Unis a accordé la [...]
Valneva publie ses résultats financiers audités et consolidés pour l’exercice 2025
18/03/2026
Chiffre d’affaires de 174,7 millions d’euros, conforme aux prévisions, dont 157,9 millions de ventes de produits Solide position de trésorerie de 109,7 millions d’euros et flexibilité financière renforcée suite au [...]
Ipsen présente le potentiel transformateur de son pipeline d’immuno oncologie précoce au congrès AACR
18/03/2026
Les données précliniques d’IPN01203 seront dévoilées lors de la convoitée session « New Drugs on the Horizon », mettant en lumière le potentiel précoce de ce nouvel activateur de cellules T à transformer la prise en [...]
UREVO Unveils CyberMega Across the DACH Region: The First Smart Treadmill Engineered for Marathon Training at Home
18/03/2026
BERLIN, March 18, 2026 (GLOBE NEWSWIRE) -- As marathon participation rises, runners increasingly require equipment that replicates the rigor and precision of road racing. To meet this demand, UREVO launched the [...]
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
18/03/2026
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, March 18, 2026 (GLOBE NEWSWIRE) -- Significant clinical and regulatory progress across entire pipeline BV100: Initiated global registrational Phase 3 (RIV- [...]
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
18/03/2026
Sanofi’s venglusta t earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026 . The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to [...]
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
18/03/2026
IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ITGA2 revealed as novel target of Ipsen’s [...]
Valneva Reports Full Year 2025 Audited Consolidated Financial Results
18/03/2026
Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt [...]
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
18/03/2026
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
18/03/2026
SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten [...]
Mesoblast to Host R&D Day on April 8, 2026
18/03/2026
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8 [...]
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026
18/03/2026
ROCKVILLE, Md. and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the [...]
NatureGlyco Blood Support Claims Evaluated: The Proven Glyco Care Formula for Healthy Blood Sugar Support
18/03/2026
A 2026 company-issued informational report covering NatureGlyco's product descriptions, ingredient references, pricing, subscription terms, and consumer verification points for adults researching blood sugar support [...]
Blood Sugar Harmony Liquid Drops Ingredients Disclosed: Complete Details Revealed
18/03/2026
SugarHarmony Research has released ingredient reference materials outlining the compounds associated with Blood Sugar Harmony Liquid Drops, citing scientific references and ingredient context as part of its published [...]
DentaBiome Claims Evaluated: 2026 Oral Postbiotic Consumer Warning Report Issued
18/03/2026
A 2026 consumer warning report examining DentaBiome's oral postbiotic formula, how FabM acid-lock and 30-second kitchen method claims relate to published research, the ingredient research context commonly cited in this [...]
MEDVi GLP-1 Weight Loss Claims Evaluated: 2026 Report Examining "Most Trusted Online Medical Care" Positioning, Telehealth Structure, and Regulatory Context
18/03/2026
A 2026 informational evaluation of MEDVi's GLP-1 weight loss program structure, compounded semaglutide and branded Ozempic access pathways, published pricing disclosures, three-entity telehealth model, refund terms, and [...]
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
17/03/2026
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March 2026) Immunocore [...]
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
17/03/2026
WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s oral KAT6A [...]

Pages